# Protein Kinase CK2 Inhibition Represents a Pharmacological Chance for the Treatment of Skin Diseases

## TL;DR

This paper reviews how inhibiting the protein kinase CK2 could offer new treatments for skin diseases like psoriasis and skin cancer.

## Contribution

The paper highlights CK2 as a novel pharmacological target for dermatological therapies and summarizes preclinical evidence for its inhibition.

## Key findings

- CK2 overactivation contributes to psoriasis through STAT3 and Akt pathways.
- CK2 inhibitors like CX-4945 show therapeutic potential in preclinical models of skin diseases.
- Combination therapies with CK2 inhibitors may enhance treatment efficacy and reduce side effects.

## Abstract

Protein kinase CK2 has emerged as a pivotal regulator of cellular processes involved in skin homeostasis, including cell proliferation, differentiation and inflammatory response regulation. In fact, CK2 activity dysregulation is implicated in the pathogenesis of different skin diseases, such as psoriasis, cancer and inflammatory dermatoses. CK2 overactivation fosters keratinocyte proliferation and pro-inflammatory cytokine production through the STAT3 and Akt pathways in psoriasis, thus contributing to epidermal hyperplasia and inflammation. In the realm of oncology, CK2 overexpression correlates with tumor progression, facilitating cell survival and metastasis in melanoma and non-melanoma skin cancers. Pharmacological inhibition of CK2 has demonstrated therapeutic potential, with CX-4945 (Silmitasertib) as the most studied adenosine triphosphate-competitive inhibitor (ATP-competitive inhibitor). Preclinical models reveal that CK2 inhibitors effectively mitigate pathological features of psoriasis, regulate keratinocyte differentiation, and suppress tumor growth in skin cancers. These inhibitors also potentiate the efficacy of conventional chemotherapeutics and exhibit anti-inflammatory effects in dermatological conditions. Future research will aim to enhance the specificity and delivery of CK2-targeting therapies, including topical formulations, to minimize systemic side effects. Combination therapies integrating CK2 inhibitors with other agents might offer synergistic benefits in managing skin diseases. This review underscores CK2’s critical role in skin and its therapeutic potential as a pharmacological target, advocating for innovative approaches to harness CK2 inhibition in dermatology.